Navigation Links
Adult Trial Frame

ProductsAdult Trial Frame
Company Richmond Products, Inc.
Item Adult Trial Frame
Features Accommodates three in front 38mm lenses in front and one in behind. Clear, precisely printed scales. Nose bridge is foam covered for comfort.
Description This quality Universal Trial Frame comes at a very attractive price.

The following adjustments can be made:

  • Temple angle
  • Temple length 4 1/8" to 5 1/2" (98 to 135mm)
  • Nose bridge height 0-14mm
  • Nose angle 0 to 30
  • PD adjustable 24 to 40mm on each side (48mm to 80mm total both eyes)
  • Axial calibration on each lens: left - 120 to 0 to 135 , right - 45 to 180 to 60
  • Lens rotation is full 360
Info Richmond Products, Inc.Call Richmond Products, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-435-4770

Customer Service: 505-275-2406
Web site: http://www.richmondproducts.com

Related medicine products :

1. Half Eye Trial Frame - Adult
2. Adjustable Trial Frame - Adult
3. Pediatric and Adult Opticokinetic Drum
4. Mayfield Disposable Adult (plastic) Skull Pins
5. Mayfield Reusable Adult Skull Pins
6. Gardener Reusable Adult Skull Pins
7. Mayfield Adult Horseshoe Headrest
8. Clear, Universal, Adult
9. Adult One-Piece Cystoscopes
10. Microcuff Adult (ICU) Tracheal Tubes
11. Portex Nu-Trake® Adult Cricothyrotomy Kit
Other Medicine News:Health News:New upper limit defined for normal ALT in adolescent males 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 3Health News:Former Texas Assistant Attorney General Pat O'Connell Joins Baron & Budd, P.C., to Lead Whistleblower Litigation Practice 2Health News:American Imaging Management Enters into Agreement with Scott & White Health Plan 2Health News:Regence Partners with Multnomah Education Service District to Bring Free Health Services to more than 20,000 Students in Need 2Health News:Regence Partners with Multnomah Education Service District to Bring Free Health Services to more than 20,000 Students in Need 3Health News:UCSF Medical Center using newest high-tech tool for brain disorders 2
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4